Baxter International Inc. (BAX)
BAX Price and Sentiment
BAX Latest news
Baxter's (BAX) third-quarter results are likely to reflect growth in its Acute Therapies business.
Baxter (BAX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Baxter and bioMérieux Announce CE Mark for NEPHROCLEAR™ CCL14 Test to Predict Persistent Severe Acute Kidney Injury2021-10-21 17:00
DEERFIELD, Ill. & MARCY L'ETOILE, France--(BUSINESS WIRE)--Baxter International Inc. (NYSE:BAX), a global leader in acute care, and bioMérieux (EPA:BIM), a global leader in in vitro diagnostics, today announced the CE marking of the NEPHROCLEAR™ CCL14 Test. The NEPHROCLEAR™ CCL14 Test is designed to predict persistent severe acute kidney injury (PS-AKI) and can be used to support timely clinical decision-making and care pathways. The companies intend to commercially launch the NEPHROCLEAR™ CCL1
DEERFIELD, Ill.--(BUSINESS WIRE)--Baxter International Inc. (NYSE:BAX), a leading global medical products company, will present at the Credit Suisse 30th Annual Virtual Healthcare Conference on Monday, November 8, 2021. Jay Saccaro, Baxter's chief financial officer, is scheduled to present at 8:50 a.m. Eastern Time. The live webcast of Baxter's presentation can be accessed at www.baxter.com and will be available for replay through November 7, 2022. About Baxter Every day, millions of patients a
We believe that Baxter stock is a good buying opportunity at the present time. BAX stock trades near $81 currently and it is, in fact, down 13% from its pre-Covid high of $93 in February 2020 – just before the coronavirus pandemic hit the world.
Baxter Presents Critical Care Data at 34th Annual European Society of Intensive Care Medicine LIVES Congress2021-10-05 08:00
DEERFIELD, Ill.--(BUSINESS WIRE)--Baxter presents critical care data at European Society of Intensive Care Medicine (ESICM) LIVES congress
DEERFIELD, Ill.--(BUSINESS WIRE)--Baxter International Inc. (NYSE:BAX), a leading global medical products company, will host a conference call to discuss its third-quarter 2021 financial results on Thursday, October 28, 2021 at 7:30 a.m. Central Time. To participate in this conference call please follow this link http://www.directeventreg.com/registration/event/3534264 to pre-register for the call and receive the call information. This call is also being webcast and can be accessed through Baxt
Baxter's (BAX) norepinephrine can improve speed, efficiency and safety of treatment during critical care situations in hospital settings, and minimize compounding errors or touch contamination risks.
Baxter Announces U.S. FDA Approval and Launch of Ready-to-use Cardiovascular Medicine Norepinephrine in Premix Formulation2021-09-23 09:00
DEERFIELD, Ill.--(BUSINESS WIRE)--Baxter announced the U.S. FDA approval and commercial launch of premix Norepinephrine Bitartrate in 5% Dextrose Injection (norepinephrine).
The market is 30% overvalued, and September is historically a time when many corrections begin. Fortunately, there are plenty of high-yield/low volatility blue chips to choose from.